We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

Consultation launches on the biggest shake-up of NICE's HealthTech programme to date. More innovative healthcare technologies could soon be adopted by the NHS under reforms proposed today by NICE.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

There is a simple discount patient access scheme for elacestrant. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact [email protected] ...

Use intravascular lithotripsy as an option to treat calcified coronary arteries during percutaneous coronary intervention with standard arrangements in place for clinical governance, consent and audit ...

A list of downloadable documents created during development.

Standard endovascular treatment options for modifying calcium or plaque during percutaneous coronary intervention (PCI) include balloon angioplasty using standard or high-pressure non-compliant ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...